3,018 results match your criteria Antiphospholipid Antibody Syndrome and Pregnancy


"APS pregnancy - The offspring".

Lupus 2020 Aug 4:961203320947154. Epub 2020 Aug 4.

Department of Obstetrics and Gynecology, I.M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia.

Background: Antiphospholipid antibody syndrome (APS) is an autoimmune disease that affects women in childbearing age. In recent years, great improvements were achieved in the management of pregnancies in these women. Prematurity could be an issue in these pregnancies, mainly due to the direct pathogenic effect of antiphospholipid antibodies (aPL) on the placental surface. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0961203320947154DOI Listing

Neurologic complications of medical conditions in pregnancy.

Authors:
Mary A O'Neal

Handb Clin Neurol 2020 ;171:215-225

Department of Neurology, Brigham and Women's Hospital, Boston, MA, United States. Electronic address:

This chapter discusses some of the neurologic complications of medical diseases that may occur in pregnancy. It reviews both the effects of pregnancy on the underlying disorder and how the medical condition may influence pregnancy outcomes. The most up-to-date information about risk stratification and disease management is presented. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/B978-0-444-64239-4.00012-6DOI Listing
January 2020

Outcomes of Pregnancy in Women With Inflammatory Myositis: A Cohort Study From India.

J Clin Rheumatol 2020 Aug;26(5):165-168

From the Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.

Objectives: Idiopathic inflammatory myositis (IIM) commonly affects women in the childbearing age group. Both disease activity and immunosuppressants used may have adverse effects on fertility and outcomes of pregnancy. We explored these outcomes in a cohort of women with IIM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RHU.0000000000000996DOI Listing

Understanding and Preventing Placenta-Mediated Pregnancy Complications.

Hamostaseologie 2020 Aug 29;40(3):356-363. Epub 2020 Jul 29.

Department of Haematology, School of Medicine, University College Dublin, Rotunda Hospital and Mater University Hospital, Irish Network for VTE Research (INViTE), Dublin, Ireland.

Placenta-mediated pregnancy complications are clinically important conditions and include preeclampsia, placental abruption, intrauterine growth restriction, and late fetal loss. Pathophysiology is complex, and may be linked to prothrombotic disorders such as antiphospholipid syndrome, whose understanding is still evolving. In this narrative review, we will present the latest evidence to better understand hemostatic mechanisms of preeclampsia, as well as in women with placenta-mediated pregnancy complications and inherited thrombophilia or antiphospholipid antibodies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/a-1184-8388DOI Listing

The role of thrombospondin-1 in the pathogenesis of antiphospholipid syndrome.

J Autoimmun 2020 Jul 21:102527. Epub 2020 Jul 21.

Department of Pathophysiology, Medical School, National and Kapodistrian University of Athens, Greece. Electronic address:

Objective: Antiphospholipid syndrome (APS) is an acquired thrombophilia characterized by recurrent thrombosis and/or pregnancy morbidity, in the presence of antibodies to β2 glycoprotein-I (β2GPI), prothrombin or Lupus anticoagulant (LA). Anti-β2GPI antibodies recognize complexes of β2GPI dimers with CXCL4 chemokine and activate platelets. Thrombospondin 1 (TSP-1) is secreted by platelets and exhibits prothrombotic and proinflammatory properties. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaut.2020.102527DOI Listing

Is There an Additional Value in Detecting Anticardiolipin and Anti-β2 glycoprotein I IgA Antibodies in the Antiphospholipid Syndrome?

Thromb Haemost 2020 Jul 21. Epub 2020 Jul 21.

Coagulation Laboratory, Department of Diagnostic Sciences, Ghent University Hospital, Gent, Belgium.

Background:  Anticardiolipin (aCL) and anti-β2 glycoprotein I (aβ2GPI) immunoglobulin A (IgA) antiphospholipid antibodies (aPL) have shown to associate with thrombosis and pregnancy morbidity. However, inclusion of IgA aPL in the classification criteria of the antiphospholipid syndrome (APS) has been debated. We investigated the value of aCL and aβ2GPI IgA aPL in the detection of thrombosis and pregnancy morbidity in addition to the current aPL panel for APS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0040-1714653DOI Listing

Intravenous immunoglobulin for the secondary prevention of stillbirth in obstetric antiphospholipid syndrome: A case series and systematic review of literature.

Autoimmun Rev 2020 Jul 16:102620. Epub 2020 Jul 16.

Department of Biomedical, Experimental and Clinical Sciences-Division of Obstetrics and Gynaecology, University of Florence, Florence, Italy.

Objective: To evaluate the efficacy and safety of intravenous immunoglobulin (IVIg) in secondary prevention of pregnancy complications for patients with obstetric antiphospholipid syndrome (APS) and history of stillbirth.

Methods: We described three cases of obstetric APS patients with history of stillbirth treated with IVIg in four pregnancies. In addition, we conducted a systematic literature review on the use of IVIg in obstetric APS with history of stillbirth. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102620DOI Listing

Risk factors for pregnancy failure in patients with antiphospholipid antibody positivity and prior pregnancy losses: A retrospective study.

J Reprod Immunol 2020 Jun 20;141:103171. Epub 2020 Jun 20.

Department of Rheumatology and Immunology, Peking University Third Hospital, 49 North Garden Road, Haidian District, Beijing, 100191, People's Republic of China. Electronic address:

Objectives: To analyze the risk factors associated with pregnancy failure in patients with positive antiphospholipid antibodies (aPL) and prior pregnancy losses, with or without a diagnosis of antiphospholipid syndrome.

Methods: We retrospectively reviewed the medical records of all the pregnant patients with positive aPL that visited the Peking University Third Hospital on an inpatient or outpatient basis from 2010 to 2019. According to the pregnancy outcome during this study, patients were divided into successful and unsuccessful groups. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jri.2020.103171DOI Listing

[Clinical features and diagnosis of Ph - negative myeloproliferative neoplasms occurring in conjunction with the antiphospholipid syndrome].

Ter Arkh 2019 Jul 15;91(7):93-99. Epub 2019 Jul 15.

National Research Center for Hematology.

Thrombosis is a serious and extremely dangerous disease that has a negative impact on the quality and longevity. Antiphospholipid syndrome (APS) is a pathology characterized by recurring venous, arterial, microvasculature thrombosis, pregnancy pathology with loss of the fetus and the synthesis of antiphospholipid antibodies. A high risk of thrombotic complications is also observed in patients with myeloproliferative neoplasms (MPN). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26442/00403660.2019.07.000324DOI Listing

Validation of the adjusted global antiphospholipid syndrome score in a single centre cohort of APS patients from Turkey.

J Thromb Thrombolysis 2020 Jun 25. Epub 2020 Jun 25.

Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Capa, Fatih, 34093, Istanbul, Turkey.

The adjusted global antiphospholipid syndrome score (aGAPSS) is a recently developed thrombotic risk assessment score that considers the antiphospholipid antibody (aPL) profile and conventional cardiovascular risk factors. In this retrospective study, we aimed to evaluate the validity of the aGAPSS in predicting clinical manifestations (criteria and extra-criteria) of antiphospholipid syndrome (APS) in a single centre cohort of patients. Ninety-eight patients with APS ± systemic lupus erythematosus (SLE) were classified according to clinical manifestations as vascular thrombosis (VT), pregnancy morbidity (PM) or both (VT + PM). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-020-02195-4DOI Listing

The β2-glycoprotein I/HLA-DR complex is the major autoantibody target in obstetric antiphospholipid syndrome.

Arthritis Rheumatol 2020 Jun 24. Epub 2020 Jun 24.

Kobe University Graduate School of Medicine, Kobe, Japan.

Objectives: The clinical manifestations of antiphospholipid syndrome (APS) include vascular thrombosis and pregnancy morbidity, including recurrent pregnancy loss (RPL). However, more than half of RPL patients never determine the cause of their RPL. Recently, β2-glycoprotein I (β2GPI) complexed with human leukocyte antigen class II molecules (β2GPI/HLA-II) was found to be a major autoantibody target in APS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/art.41410DOI Listing

Competing-risks model for prediction of small-for-gestational-age neonate from maternal characteristics and medical history.

Ultrasound Obstet Gynecol 2020 Aug 10;56(2):196-205. Epub 2020 Jul 10.

Fetal Medicine Research Institute, King's College Hospital, London, UK.

Background: The established method of identifying a group of women at high risk of delivering a small-for-gestational-age (SGA) neonate, requiring increased surveillance, is use of risk scoring systems based on maternal demographic characteristics and medical history. Although this approach is relatively simple to perform, it does not provide patient-specific risks and has an uncertain performance in predicting SGA. Another approach to predict delivery of a SGA neonate is to use logistic regression models that combine maternal factors with first-trimester biomarkers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/uog.22129DOI Listing

Complement-Mediated Disorders in Pregnancy.

Adv Chronic Kidney Dis 2020 Mar;27(2):155-164

Department of Nephrology/Medicine, Jacobi Medical Center at Albert Einstein College of Medicine, Bronx, NY. Electronic address:

Complement-mediated disorders in pregnancy span a large spectrum and have been implicated in all three complement pathways: classical, lectin, and alternative. Our understanding of these disorders in recent years has advanced due to a better understanding of complement regulatory proteins, such as complement factor H, complement factor I, membrane cofactor protein, and thrombomodulin that particularly affect the alternative complement pathway. Enthusiasm in genotyping for mutations that encode these proteins has allowed us to study the presence of genetic variants which may predispose women to develop conditions such as pregnancy-associated hemolytic uremic syndrome (P-aHUS), thrombotic thrombocytopenic purpura, preeclampsia/hemolysis, elevated liver enzymes, low platelets (HELLP), systemic lupus erythematosus/antiphospholipid syndrome, and peripartum cardiomyopathy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.ackd.2020.01.002DOI Listing

17β-Estradiol Promotes Proinflammatory and Procoagulatory Phenotype of Innate Immune Cells in the Presence of Antiphospholipid Antibodies.

Biomedicines 2020 Jun 15;8(6). Epub 2020 Jun 15.

Department of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc and Faculty Hospital, 775 15 Olomouc, Czech Republic.

Antiphospholipid syndrome (APS) is the most common cause of acquired thrombophilia and recurrent spontaneous miscarriages associated with extended persistence of antiphospholipid antibodies (aPL). How circulating aPL and high-17β-estradiol (E2) environment contribute to the pregnancy complications in APS is poorly defined. Therefore, we aimed to analyse whether E2 could be responsible for the immune cell hyperactivation in aPL- positive (lupus anticoagulant, anti-cardiolipin, anti-β2-glycoprotein) in women. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/biomedicines8060162DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7345022PMC

Significance of Anti-Phosphatidylethanolamine Antibodies in the Pathogenesis of Recurrent Pregnancy Loss.

Reprod Sci 2020 Jun 16. Epub 2020 Jun 16.

Department of Obstetrics and Gynecology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan.

Anti-phosphatidylethanolamine antibody (aPE), an anti-phospholipid autoantibody (aPL), has been proposed as a factor in recurrent pregnancy loss (RPL). However, conflicting views exist on the pathogenicity of RPL, and aPE has not yet been included in the classification criteria for antiphospholipid syndrome (APS). Here, we aimed to determine the clinical importance of examining aPE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s43032-020-00208-4DOI Listing

Long-term follow-up of antiphospholipid syndrome: real-life experience from a single center.

Lupus 2020 Aug 14;29(9):1050-1059. Epub 2020 Jun 14.

Department of Autoimmune Diseases, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Catalonia, Spain.

Objective: The objective of this paper is to assess the prevalence of the main clinical manifestations and laboratory features at disease onset and during the ensuing 10 years of a large cohort of patients with antiphospholipid syndrome (APS) from a single center.

Methods: The study included all consecutive APS patients followed longitudinally in our center from 2003 to 2013. Descriptive statistics for demographics, clinical and laboratory features and mortality were performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0961203320933009DOI Listing

[NEUROPROTECTIVE EFFECT OF AMINOGUANIDINE IN EXPERIMENTAL OBSTETRIC ANTIPHOSPHOLIPID SYNDROME].

Georgian Med News 2020 Apr(301):159-165

1I. Horbachevsky Ternopil National Medical University, Ukraine.

The aim of the research was to investigate the effect of aminoguanidine on the content of autoantibodies in the serum, nitric oxide synthesis (NO), glial fibrillary acidic protein (GFAP) content and indicators of free radical oxidation in the cerebral hemispheres of BALB/c mice with antiphospholipid syndrome (APS) on the 18th day of pregnancy. An increase in the content of autoantibodies to brain proteins (120 kDa, 150 kDa, and >170 kDa) was detected in the serum of BALB/c mice with APS on the 18th day of pregnancy. An increase in the content of GFAP (total), GFAP (49-37 kDa), NO2¯, NO3¯ and prooxidant-antioxidant system imbalance in the cerebral hemispheres of pregnant mice with APS was established. Read More

View Article

Download full-text PDF

Source

An update on the management of antiphospholipid syndrome.

Ther Adv Musculoskelet Dis 2020 27;12:1759720X20910855. Epub 2020 Apr 27.

Louise Coote Lupus Unit, Guy's Hospital, London, UK.

Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by recurrent venous or arterial thrombosis with or without pregnancy morbidity in the presence of persistent antiphospholipid (aPL) autoantibodies. Anticoagulation has, until now, formed the cornerstone of treatment but a significant proportion of patients continue to experience thrombosis and pregnancy morbidity despite this treatment. Thrombosis is the most common cause of mortality and accounts for two fifths of deaths. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1759720X20910855DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236388PMC

Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases.

Adv Rheumatol 2020 06 9;60(1):32. Epub 2020 Jun 9.

Pontifícia Universidade Católica de Campinas, Campinas, Brazil.

Hydroxychloroquine and chloroquine, also known as antimalarial drugs, are widely used in the treatment of rheumatic diseases and have recently become the focus of attention because of the ongoing COVID-19 pandemic. Rheumatologists have been using antimalarials to manage patients with chronic immune-mediated inflammatory rheumatic diseases for decades. It is an appropriate time to review their immunomodulatory and anti-inflammatory mechanisms impact on disease activity and survival of systemic lupus erythematosus patient, including antiplatelet effect, metabolic and lipid benefits. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s42358-020-00134-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7282202PMC

Clinical features associated with pregnancy outcomes in women with positive antiphospholipid antibodies and previous adverse pregnancy outcomes: a real-world prospective study.

Clin Rheumatol 2020 Jun 8. Epub 2020 Jun 8.

Department of Rheumatology and Immunology, Peking University Third Hospital, Beijing, 100191, China.

Objective: This study aims to analyze factors related to pregnancy outcomes in women with positive antiphospholipid antibodies and previous adverse pregnancy outcomes (APOs) prospectively.

Methods: Patients' characteristics were described. Factors associated with obstetric complications were analyzed using logistic regression analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10067-020-05203-3DOI Listing

Cardiovascular disease and antiphospholipid syndrome: how to predict and how to treat?

Pol Arch Intern Med 2020 Jun 3. Epub 2020 Jun 3.

The antiphospholipid syndrome (APS) is an autoimmune systemic disease characterized by a hypercoagulable state secondary to the presence of antiphospholipid antibodies (aPL) and associated to vascular thromboses and/or pregnancy complications. Although ≈60% of thrombotic manifestations is represented by venous thrombosis, also cardiovascular (CV) manifestations can occur in APS patients, comprising coronary and/or non-coronary complications. Moreover, several studies consistently showed a more significant atherosclerosis in APS patients than controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.20452/pamw.15415DOI Listing
June 2020
2.052 Impact Factor

Severe HELLP syndrome masquerading as thrombocytopenic thrombotic purpura: a case report.

BMC Nephrol 2020 May 29;21(1):204. Epub 2020 May 29.

Department of Nephrology, CHU Tenon, Assistance Publique-Hopitaux de Paris, Paris, France.

Background: Thrombotic microangiopathies (TMAs) occurring in the postpartum period may be difficult to manage. They present as the combination of mechanical hemolytic anemia and consumption thrombocytopenia due to endothelial dysfunction. The cause of this endothelial aggression can be multiple: thrombocytopenic thrombotic purpura (TTP), HELLP syndrome, antiphospholipid syndrome, atypical hemolytic and uremic syndrome or acute fatty liver of pregnancy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12882-020-01865-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260815PMC

Profiles of criteria and non-criteria anti-phospholipid autoantibodies are associated with clinical phenotypes of the antiphospholipid syndrome.

Auto Immun Highlights 2020 Dec 15;11(1). Epub 2020 May 15.

1Clinical Immunology, Angioedema and Allergy Unit, Zabludowicz Center for Autoimmune Diseases, The Chaim Sheba Medical Center, Tel-Hashomer, 52621 Israel.

Background: Specific anti-phospholipids antibodies (aPLs) are used as classification criteria of the antiphospholipid syndrome (APS). These aPLs, although essential for diagnosis, do not predict disease phenotypes, which may require specific therapies. Non-criteria aPLs are rarely evaluated and their role is yet to be defined. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13317-020-00131-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229627PMC
December 2020

Management of antiphospholipid syndrome.

Authors:
Anisur Rahman

Clin Rheumatol 2020 Jul 26;39(7):2111-2114. Epub 2020 May 26.

Centre for Rheumatology Research, Division of Medicine, University College London, London, UK.

Antiphospholipid syndrome (APS) is an autoimmune disease characterised by vascular thrombosis and/or pregnancy morbidity in the presence of persistently positive serum tests for antiphospholipid antibodies. Management of APS centres on preventing these clinical events and in preventing chronic damage caused by these events. In patients with thrombotic APS, long-term anticoagulation is recommended in the majority of cases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10067-020-05183-4DOI Listing

Prevention of Pregnancy Complications in Antiphospholipid Syndrome.

Hamostaseologie 2020 Jun 26;40(2):174-183. Epub 2020 May 26.

amedes MVZ wagnerstibbe für Laboratoriumsmedizin, Hämostaseologie, Humangenetik und Mikrobiologie, Hannover, Germany.

Despite a lot of research on antiphospholipid antibodies (aPL), standardization of test systems, and better definition of its clinical symptoms, the pathomechanism of this acquired autoimmune disease is not yet fully explained. Progress in treatment increased the live birth rate in 70 to 80% of women suffering from obstetric antiphospholipid syndrome (OAPS). However, still 20 to 30% will develop adverse pregnancy outcome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/a-1113-0689DOI Listing

Antiphospholipid syndrome.

Authors:
Michelle Petri

Transl Res 2020 May 12. Epub 2020 May 12.

Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address:

Antiphospholipid syndrome is one of the more common acquired causes of hypercoagulability. Its major presentations are thrombotic (arterial, venous, or microvascular) and pregnancy morbidity (miscarriages, late intrauterine fetal demise, and severe pre-eclampsia). Classification criteria include 3 different antiphospholipid antibodies: lupus anticoagulant, anticardiolipin, and anti-beta 2 glycoprotein I. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.trsl.2020.04.006DOI Listing

Obstetric antiphospholipid syndrome is not associated with an increased risk of subclinical atherosclerosis.

Rheumatology (Oxford) 2020 May 10. Epub 2020 May 10.

Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA) Italy.

Objectives: The persistent positivity of aPLs, either isolated or associated with thrombotic and/or obstetric events (APS), has been associated with the increase of intima-media thickness (IMT) and carotid plaques. Despite the fact that aPLs can promote both thrombotic and obstetric complications, some pathogenic differences have been documented between the two entities. This study aimed to evaluate whether the atherosclerotic risk differs between subjects with obstetric and thrombotic APS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/rheumatology/keaa116DOI Listing

Antiphospholipid antibody-activated NETs exacerbate trophoblast and endothelial cell injury in obstetric antiphospholipid syndrome.

J Cell Mol Med 2020 Jun 5;24(12):6690-6703. Epub 2020 May 5.

Department of Obstetrics and Gynaecology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.

Despite the widespread use of antiplatelets and anticoagulants, women with antiphospholipid syndrome (APS) may face pregnancy complications associated with placental dysplasia. Neutrophil extracellular traps (NETs) are involved in the pathogenesis of many autoimmune diseases, including vascular APS; however, their role in obstetric APS is unclear. Herein, we investigated the role of NETs by quantifying cell-free DNA and NET marker levels. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jcmm.15321DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299718PMC

Circulating Nucleic Acids in Maternal Plasma and Serum in Pregnancy Complications: Are They Really Useful in Clinical Practice? A Systematic Review.

Mol Diagn Ther 2020 Aug;24(4):409-431

Division of Obstetrics and Prenatal Medicine, Department of Medicine and Surgery (DIMEC) Sant'Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.

Objective: A systematic review was carried out to summarize the available evidence to assess whether circulating nucleic acids in maternal plasma and serum (CNAPS) have the potential to serve as extra and independent markers for the prediction and/or progression monitoring of the most common and severe complications of pregnancy, including preeclampsia, intrauterine growth restriction, preterm delivery, morbidly adherent placenta, gestational diabetes, antiphospholipid syndrome, threatened abortion, intrahepatic cholestasis of pregnancy, and hyperemesis gravidarum.

Method: A comprehensive literature search of the MEDLINE (PubMed), EMBASE, and ISI Web of Knowledge databases was conducted to identify relevant studies that included amounts of CNAPS in the abovementioned pregnancy complications.

Results: Eighty-three studies met the eligibility criteria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40291-020-00468-5DOI Listing

Hyperoside attenuates pregnancy loss through activating autophagy and suppressing inflammation in a rat model.

Life Sci 2020 Aug 29;254:117735. Epub 2020 Apr 29.

Department of Reproductive Medicine, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, People's Republic of China. Electronic address:

Aims: Recurrent pregnancy loss (RPL) is one of the most common obstetrical diseases, which is a manifestation of antiphospholipid syndrome (APS) with no effective therapy methods. Autophagy and inflammatory responses both play an important role in the pathogenesis of RPL and hyperoside has been demonstrated to have multifarious bioactivities including enhancing autophagy and anti-inflammation. This study aims to investigate the effect of hyperoside on anticardiolipin (aCL)-IgG fractions-induced pregnancy loss. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lfs.2020.117735DOI Listing

Antiphospholipid syndrome presenting as treatment resistant bipolar disorder and thrombocytopenia in a young male.

J Neuroimmunol 2020 Jun 11;343:577238. Epub 2020 Apr 11.

Department of Pathology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.

Antiphospholipid syndrome (APS), an autoantibody mediated disease, is characterized by presence of antibodies against the proteins bound to the phospholipid membranes. The antibodies are predominantly formed against beta-2-glycoprotein I (b2GPI) which is considered pathogenic, but presence of lupus anticoagulant is a predictor of thrombotic events. The thrombotic events in APS may manifest as venous or arterial or small vessel thrombosis in any tissue or organ and pregnancy related complications namely, recurrent (three or more) and early spontaneous miscarriages before 10 weeks of gestation or unexplained deaths of normal fetus at or beyond 10 weeks, eclampsia or severe pre-eclampsia, intra-uterine growth retardation and pre-term births. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jneuroim.2020.577238DOI Listing

[Lupus and thrombophilia : Antiphospholipid syndrome].

Z Rheumatol 2020 May;79(4):332-341

Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Deutschland.

Even early on thromboembolic events were observed in patients with systemic lupus erythematosus (SLE) until the antiphospholipid syndrome (APS) was described in the 1980s as an independent disorder. The APS is a systemic autoimmune disease often overlapping with SLE in which antiphospholipid autoantibodies, including lupus anticoagulant, can cause a hypercoagulation state, which clinically by definition is manifested as arterial and venous occlusions or pregnancy complications. The pathophysiology has not yet been entirely delineated and the clinical spectrum of associated concomitant manifestations is large. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00393-020-00786-3DOI Listing

A Rare Case of Catastrophic Antiphospholipid Antibody Syndrome: A Case Report and Review of Traditional Cardiovascular Risk Factors Implicated in Disease Occurrence.

Cureus 2020 Mar 9;12(3):e7221. Epub 2020 Mar 9.

Hematology - Oncology, Crozer Chester Medical Center, Upland, USA.

Antiphospholipid syndrome (APS) is a multisystem autoimmune condition characterized by recurrent thrombosis and/or recurrent pregnancy loss. Clinical manifestations include minor clots to clots involving multiple organ systems, termed catastrophic antiphospholipid syndrome (CAPS). The interaction of several autoantibodies, anti-beta-2-glycoprotein 1 antibodies, lupus anticoagulant, and anticardiolipin antibody with plasma proteins is associated with a heightened procoagulant state. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.7221DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141797PMC

Pregnancy-associated Inflammatory Myofibroblastic Tumors of the Uterus Are Clinically Distinct and Highly Enriched for TIMP3-ALK and THBS1-ALK Fusions.

Am J Surg Pathol 2020 Jul;44(7):970-981

Department of Pathology, Stanford University School of Medicine, Stanford, CA.

As inflammatory myofibroblastic tumors (IMTs) have become more widely recognized in the female genital tract, an intriguing subset of uterine tumors associated with pregnancy has emerged. Whether uterine IMTs occurring in the setting of pregnancy are clinically or biologically distinct from other uterine IMTs is unknown. Furthermore, little is known about the perinatal factors that may influence the development of these tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000001481DOI Listing

[Management of the antiphospholipid syndrome in adults].

Rev Med Suisse 2020 Apr;16(689):670-674

Service d'immunologie et allergologie, Département de médecine interne, CHUV, 1011 Lausanne.

The antiphospholipid syndrome (APS) is a complex autoimmune -disease characterized by the expression of antiphospholipid -antibodies (APL) and a variety of clinical presentation. The latest classification defines APS by the occurrence of vascular thrombosis and/or typical obstetrical morbidity together with persistently -detectable APL at least 12 weeks apart. The latest recommendation proposes a risk profile based on the type and titer of APL detected, in order to guide the intensity of prophylactic measures. Read More

View Article

Download full-text PDF

Source

Antiphospholipid syndrome: a case report with an unusual wide spectrum of clinical manifestations.

Auto Immun Highlights 2019 Dec 19;10(1). Epub 2019 Oct 19.

Department of Interdisciplinary Medicine, University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124 Bari, Italy.

Background: Antiphospholipid syndrome (APS) is an autoimmune disease characterized by the occurrence of venous and/or arterial thrombosis, and the detection of circulating antiphospholipid antibodies. The classification criteria for definite APS are actually met when at least one clinical criterion (thrombosis or pregnancy morbidity) is present in association of one laboratory criterion (LAC, aCL antibody or aβ2GPI antibody present on two or more occasions, at least 12 weeks a part), and thrombosis should be confirmed by objective validated criteria. The average age of primary APS patients has been reported to be about 35-40 years and the disease is more common in women than in men. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13317-019-0119-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065311PMC
December 2019

[Pregnancy with lupus erythematosus-an update].

Z Rheumatol 2020 May;79(4):359-366

Poliklinik für Rheumatologie und Hiller Forschungszentrum, Universitätsklinikum Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Deutschland.

Current research in the field of systemic lupus erythematosus (SLE) and pregnancy focuses on predictors of adverse pregnancy outcomes, the safety and efficacy of hydroxychloroquine (HCQ) in pregnancy and the importance of preconception counselling. In particular, the prospective predictors of pregnancy outcome: biomarkers in antiphospholipid antibody syndrome and SLE (PROMISSE) study adds to the understanding of risk factors for adverse outcomes. There is increasing evidence of the numerous benefits associated with continuing HCQ treatment in pregnancy and for the use of low-dose acetylsalicylic acid in the prevention of preeclampsia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00393-020-00772-9DOI Listing

The study of factors associated with pregnancy outcomes in patients with systemic lupus erythematosus.

BMC Res Notes 2020 Mar 30;13(1):185. Epub 2020 Mar 30.

Department of Biostatistics and Public Health, Faculty of Health, Kashan University of Medical Sciences, Pezeshk Blvd, 5th of Qotb-e Ravandi Blvd, P.O.Box: 8715973449, Kashan, Iran.

Objectives: Systemic lupus erythematosus (SLE) is an autoimmune disease that can lead to unfavorable pregnancy complications in women. This study aimed to evaluate the factors associated with pregnancy outcomes in patients with SLE.

Results: Fifty-nine pregnant women with SLE (121 pregnancies) participated in this retrospective cohort study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13104-020-05039-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108499PMC

Anticardiolipin from Periodontitis Patients Impact Fetal Loss and Annexin V.

J Dent Res 2020 Jul 23;99(7):797-803. Epub 2020 Mar 23.

Department of Periodontics, Virginia Commonwealth University School of Dentistry, Richmond, VA, USA.

Anticardiolipin antibodies, found at elevated serum concentrations in 15% to 20% of individuals with periodontitis, are associated with adverse pregnancy outcomes, thrombotic conditions, and accelerated atherosclerosis in autoimmune disease such as the antiphospholipid syndrome. Our previous studies demonstrated that antibodies raised in mice against caused fetal loss in a mouse pregnancy model due to anticardiolipin antibodies. Such antibodies are induced via molecular mimicry with the serum protein β2-glycoprotein 1 (β2GP1), the target antigen of anticardiolipin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0022034520913244DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7313349PMC

Low frequency of flares during pregnancy and post-partum in stable lupus patients.

Arthritis Res Ther 2020 03 19;22(1):52. Epub 2020 Mar 19.

Hospital for Special Surgery, 535 E 70th Street, New York, NY, 10021, USA.

Background: Lupus patients are at risk for pregnancy loss, and it has been generally accepted that women with SLE should have low disease activity prior to conception. However, there are conflicting results regarding the effect of pregnancy on SLE flares. This study aims to identify predictors of flares during and after pregnancy in SLE patients with inactive or stable disease activity during the first trimester and to characterize and estimate the frequency of post-partum flares in these patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13075-020-2139-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081564PMC

[Antiphospholipid syndrome : Update on diagnostics and management].

Z Rheumatol 2020 Apr;79(3):255-266

Klinik für Rheumatologie und Klinische Immunologie, Charité Universitätsmedizin Berlin, Berlin, Deutschland.

Antiphospholipid syndrome (APS) was first identified in patients with systemic lupus erythematosus (SLE) and frequent occurrence of thromboembolic complications and miscarriages accompanied by detection of anticardiolipin antibodies (aCL). When APS was also later found without an underlying SLE, the so-called primary APS was distinguished from its secondary form with SLE. Even more specific than aCL are the lupus anticoagulant (LA) and antibodies against beta‑2 glycoprotein I (aB2GP I). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00393-020-00759-6DOI Listing

A rare case of mesenteric vessel thrombosis post caesarian section-An underdiagnosed entity.

Int J Surg Case Rep 2020 19;68:170-173. Epub 2020 Feb 19.

Department of Pathology, Pt. B D Sharma PGIMS, Rohtak, India. Electronic address:

Introduction: Respiratory distress is an uncommon clinical event after caesarean section and occurs due to pulmonary thromboembolism. Various causes of pulmonary thromboembolism are thrombophlebitis, ovarian venous thrombosis and mesenteric vein thrombosis.

Presentation Of Case: We report a case of 30 year old female who presented with respiratory distress after eight days of uneventful caesarian section. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijscr.2020.02.029DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066031PMC
February 2020

[Obstetrics complications of systemic lupus erythematosus and antiphospholipid syndrome: A multidisciplinary management].

Gynecol Obstet Fertil Senol 2020 May 7;48(5):448-452. Epub 2020 Mar 7.

Service de gynécologie-obstétrique, CHU de Bordeaux, place Amélie-abat-Léon, 33076 Bordeaux, France.

The main autoimmune diseases responsible for obstetric complications are systemic lupus erythematosus and antiphospholipid syndrome. They are particularly associated with an increased risk of miscarriage, stillbirth, intrauterine growth restriction, prematurity and pre-eclampsia. Therapeutics to prevent its complications are mainly low dose aspirin and low molecular weight heparins. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gofs.2020.03.005DOI Listing

Early Onset Severe Hypertensive Disease in Pregnancy and Screening for Antiphospholipid Syndrome.

AJP Rep 2020 Jan 4;10(1):e32-e36. Epub 2020 Mar 4.

Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, San Francisco, California.

 Although preterm delivery (PTD) before 34 weeks for severe hypertensive disease is a diagnostic criterion for antiphospholipid syndrome (APS), there is no consensus regarding testing for antiphospholipid antibodies (aPL) in this setting. We aim to describe the frequency of and the characteristics associated with inpatient aPL testing in this population.  In this retrospective study of PTD before 34 weeks for severe hypertensive disease, charts were reviewed for aPL testing, gestational age at delivery, fetal complications, and severity of maternal disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0040-1702926DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7056392PMC
January 2020

Adverse pregnancy outcomes and subsequent development of connective tissue disease in the UK: an epidemiological study.

BJOG 2020 07 25;127(8):941-949. Epub 2020 Mar 25.

Faculty of Biological, Medical and Human Sciences, School of Medical Sciences, Maternal and Fetal Health Research Centre, University of Manchester, Manchester, UK.

Objective: This study assessed prevalence of connective tissue disease (CTDs), systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS) and antiphospholipid antibodies (aPL) in women with previous adverse pregnancy outcome compared with uncomplicated livebirths.

Design: Retrospective case-control study.

Setting: UK Primary Care. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1471-0528.16191DOI Listing

Preeclampsia before fetal viability in women with primary antiphospholipid syndrome- materno-fetal outcomes in a series of 7 cases.

J Reprod Immunol 2020 04 22;138:103101. Epub 2020 Feb 22.

Medical University Graz, 8036, Graz, Austria.

Introduction: Preeclampsia complicates about 10-17 % of pregnancies with antiphospholipid syndrome (APS). It is often severe and might occur sometimes at early gestation. The development of preeclampsia before fetal viability is a huge challenge for obstetricians and demands an intensive discussion regarding the therapeutical options. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jri.2020.103101DOI Listing

Are pregnancies with lupus but without APS of good prognosis?

Autoimmun Rev 2020 Apr 27;19(4):102489. Epub 2020 Feb 27.

Univ. Lille, EA 2694: Epidémiologie et qualité des soins, F-59000 Lille, France; Univ Lille, CHU Lille, Pôle Femme Mère Nouveau-né, F-59000 Lille, France.

Background: Pregnancies in women with systemic lupus erythematosus (SLE) are at risk of unfavorable perinatal outcomes, especially when antiphospholipid antibody syndrome (APS) is present. Their prognosis is less clear in other situations.

Objectives: To assess pregnancy prognosis in women with SLE but not APS compared with a control series and determine the poor prognostic factors, if any, detectable before 15 weeks' gestation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102489DOI Listing

Recurrent pregnancy loss: diagnostic workup after two or three pregnancy losses? A systematic review of the literature and meta-analysis.

Hum Reprod Update 2020 Apr;26(3):356-367

Centre for Reproductive Medicine, Department of Obstetrics and Gynaecology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

Background: Recurrent pregnancy loss (RPL) occurs in 1-3% of all couples trying to conceive. No consensus exists regarding when to perform testing for risk factors in couples with RPL. Some guidelines recommend testing if a patient has had two pregnancy losses whereas others advise to test after three losses. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/humupd/dmz048DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7161667PMC

The Predictive Value of d-Dimer Test for Venous Thromboembolism During Puerperium: A Prospective Cohort Study.

Clin Appl Thromb Hemost 2020 Jan-Dec;26:1076029620901786

Department of Obstetrics, Women's Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China.

The aim of this study was to investigate the d-dimer for prediction of venous thromboembolism (VTE) events in puerperium and to identify other risk factors associated with the occurrence of VTE. This was a prospective observational cohort study, which included 16 127 women who gave birth after 28 weeks of gestation at Women's Hospital of Zhejiang University, School of Medicine, from January 2016 to December 2016. Data including basic maternal and fetal characteristics, pregnancy complications, and predictive biomarkers within postpartum 24 hours including d-dimer, platelet, and fibrinogen were collected for analyses. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1076029620901786DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7288823PMC
February 2020